Filing Flows › Abeona Therapeutics (ABEO) › Q1 2026
Abeona Therapeutics (ABEO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Abeona Therapeutics (ABEO) reported revenue of $8.7M for the first quarter 2026 (Q1 2026) and +61% from the quarter before. Operating margin was -264.1%, net loss $17.1M (195.8% of revenue).
Abeona Therapeutics, Q1 2026: revenue $8.7M, operating margin -264.1%, net loss $17.1M, operating cash flow −$19.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.7M | +61% | — |
| Operating profit | −$23.0M | — | — |
| Net earnings | −$17.1M | — | — |
| Operating cash flow | −$19.8M | — | — |
What changed
Revenue was $8.7M in Q1 2026, up 61% from the previous quarter.
Operating costs exceeded revenue by $23.0M, an operating margin of -264.1%. The quarter ended with a net loss of $17.1M, narrower than the previous quarter's $20.5M loss. Non-operating items added $6.0M, -35% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$19.8M. Non-cash charges added back $690K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $6.4M. Capital expenditures of $935K exceeded it, leaving free cash flow of −$20.7M.
Questions
What was Abeona Therapeutics' revenue in the first quarter 2026?
Abeona Therapeutics (ABEO) reported revenue of $8.7M for the first quarter 2026 (Q1 2026) and +61% from the quarter before.
Was Abeona Therapeutics profitable in the first quarter 2026?
Operating loss was $23.0M (-264.1% of revenue) and net loss $17.1M.